Company: ARMP
Filing Date: 2025-12-01
Form Type: 424B5
Source: 0001104659-25-117382
Chunk: 33

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 424B5
Chunk 33
---
 | 31 |

We have not authorized anyone
to provide you with information different from the information contained in or incorporated by reference in this prospectus, any applicable
prospectus supplement and any related free writing prospectus that we may authorize to be provided to you. No dealer, salesperson or other
person is authorized to give any information or to represent anything not contained or incorporated by reference in this prospectus, any
applicable prospectus supplement or any related free writing prospectus that we may authorize to be provided to you. This prospectus is
an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You
should assume that the information in this prospectus, any applicable prospectus supplement or any related free writing prospectus is
accurate only as of the date on the front of the document and that any information we have incorporated by reference is accurate only
as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, any applicable prospectus
supplement or any related free writing prospectus, or any sale of our securities. Our business, financial condition, results of operations
and prospects may have changed since that date.

<div align='center'>- 3 -

ABOUT THIS PROSPECTUS</div>

This prospectus is part of
a registration statement on Form S-3 that we filed with the U.S. Securities and Exchange Commission, or the SEC, using a “shelf”
registration process. Under this shelf registration process, we may offer and sell, either individually or in combination, in one or more
offerings, any combination of the securities described in this prospectus, for total gross proceeds of up to $100,000,000.

This prospectus provides you
with a general description of the securities we may offer. Each time we offer securities under this prospectus, we will provide a prospectus
supplement that will contain more specific information about the terms of those securities and the offering. We may also authorize one
or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. We may also
add, update or change in the prospectus supplement (and in any related free writing prospectus that we may authorize to be provided to
you) any of the information contained in this prospectus or in the documents that we have incorporated by reference into this prospectus.
We urge you to carefully read this prospectus, any applicable prospect